2021, Bolt Therapeutics presented Phase Ⅰ/Ⅱ clinical data for BDC-1001 at the ESMO meeting. 1 PR (partial remission) and 12 SD (stable disease) out of 40 evaluable patients, with an overall remission rate ORR of only 2.5% and a disease control rate DCR of 32.5%. This is not the...
He was managed in the critical care unit with continuous esmolol intravenous (IV) infusion and planned for endovascular repair. During his stay, he became disoriented and hypotensive. MRI from the brain incidentally discovered a pituitary macroadenoma measuring 2.9x2.2x3cm and recent infarcts, with...
Causal inference defines what a treatment effect is and how it may be estimated with RCTs or outside of RCTs with observational – or ‘real-world’ – data. In this review, we introduce the field of causal inference, explain what a treatment effect is and what important challenges are ...
But according to new results from the phase 3 KATHERINE trial, use of adjuvantado-trastuzumab emtansine(T-DM1;Kadcyla, Roche) in this residual disease group cuts the risk of recurrence of breast cancer or death by 50% versus trastuzumab alone. T-DM1 is an antibody–drug conjugate of trastuzum...
BFF dilemma of the month: how can I keep my best friend from feeling left out when she has to be home so much earlier than the rest of us?My BFF has an earlier curfew than the other girls in our crew. We want to have fun this summer, but she can't hang as late as we do. ...